Peninsula biotech's stock soars 73% on results of lupus trial

A Peninsula company spun out of Amgen Inc. after its acquisition of Onyx Pharmaceuticals saw its stock climb 73% Thursday on results from a study of its lead drug in people with a type of lupus. Kezar Life Sciences Inc. (NASDAQ: KZR) said people given the drug, called KZR-616, showed improvements across seven measures of disease activity in a Phase Ib study in systemic lupus erythematosus, a disease in which the immune system attacks healthy tissue and affects the skin, joins, kidneys, br ain and…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news